AQST Aquestive Therapeutics Inc

$AQST What a hot tape does to a $4.80 name when each headline hits clean. Anaphylm resubmission accepted — late Q3 / early Q4 ’26 — $5.50–$6.00 FDA files it and sets a clock — weeks later — $6.50–$7.25 Canada NDS filed — YE ’26 — $7.00–$8.00 Libervant US deal or solo launch build — before January — $8–$10 Libervant 6–11 / age-expansion PR — through 1H ’27 — $9–$11 Anaphylm US approval — ’27 — $12–$16 Anaphylm EU MAA filed — Q1 ’27 — $13–$17 Libervant US unlocked Jan ’27 + first scripts — Q1–Q2 ’27 — $14–$18 Anaphylm EU/UK approval — ’27–’28 — $16–$22 AQST-108 AD or alopecia data — ’27 — supports $20 7-product royalties + insurance uptake — ’27 run-rate — high teens to $20s

$AQST Don't forget, a huge US partnership deal for Libervant is coming before the January launch. If they don't go the partnership route that will be a $100M - $200M annual revenue stream for AQST. When Anaphylm hits the market and we start getting ins uptake over the following 9 months, we will be toying with the high teen$ to the $20's. They will be earning revs on 7 products just from the manufacturing side, royalties from their already licensed products. Before Libervant and Anaphylm, they are bringing in around $50M annually. Anaphylm is great, but at least when you buy this, you have an insurance policy, so to speak, with the current pipeline and revenue streams. Unlike other companies that are simple one trick ponies such as SPRY.

$AQST it’s time to terminate this worthless partnership with Pharmanovia who has done absolutely nothing with their Aquestive partnership since, 2022 and amended in 2023 to seek approval for Libervant 1. The 3-Year Regulatory "Cushion" According to SEC filings detailing the amended Aquestive-Pharmanovia License and Supply Agreement, Pharmanovia was granted a long runway to submit its first health authority filing. The contract dictates that either party can terminate the deal with three months' notice only if Pharmanovia fails to file for its first Regulatory Approval within three years of the amendment's effective date. Given that this amendment was executed in March 2023, the clause effectively protected Pharmanovia from immediate pressure to file until March 2026.

$AQST I have no idea on why the SI has gone up on this with the NDA right around the corner. I bought more under $5 throughout the day today in small blocks. If it goes lower Monday I'll buy more.

$AQST With PDUFA update, this will go up 6+ in no time. Algos just need clarity for movement. That BULL FLAG is so evident. 15%+ day coming soon

$AQST Modeling the scenario where Anaphyl gets FDA approval, transitions to OTC and has a strong commercial adoption (Libervant and 108 not included) (ChatGPT): Potential AQST share prices for successful OTC conversion ($38-40), strong OTC ($69-72), exceptional growth ($92-96, but $2B growth considering world-wide is $115+). As we already know, the global epinephrine market is expected to reach $5.5 to $6.1B by 2030-2034. Also, The company's current presentation identifies, not including present licensing agrrements: • Anaphylm: >$1B potential annual revenue • Libervant: >$100M • AQST-108: >$500M potential annual revenue

$AQST AQST short interest increased an additional 1.7M shares to a total of 27.2M shares thru Sep 15th. It's the highest I have ever seen it, and 3M higher than when it peaked last Dec 31st at 24.1M just before the deficiencies notification. I’m not sure why short interest continues to climb this time, as it seems to be in a much better position to gain approval from the FDA, but anything is possible. I would love to see a short interest squeeze and for the shorts to get burned badly. Please make it happen AQST / FDA.

$AQST - Thank you for highlighting the ongoing shortage of epinephrine auto-injectors. Given these supply constraints, this could be the ideal window for the FDA to grant Anaphylm a Class 1 resubmission designation to expedite its review and bring an alternative to market. What are your thoughts on the likelihood of this happening?

$AQST Before joining AQST, Matthew Greenhawt was the Chief Medical Office for the nation’s oldest and largest asthma and allergy advocacy organization (AAFA). Before that, Dr. Greenhawt, who is Board certified in both Pediatric and Allergy/Immunology, served as a professor at Children’s Hospital Colorado. Dr. Greenhawt’s work with AAFA included development of food allergy and anaphylaxis action plans, decision aids for food allergy treatment, advocacy on precautionary allergen labeling, and patient-centered research on air travel and healthcare access.

$AQST Right now, I'm not even thinking about Anaphylm. Thats on automatic. I want to see the Libervant US partnership come to life before the January launch. That will be their 5th product on the market and the largest, as Suboxone continues to wind down. Suboxone — Indivior, U.S. and other markets Sympazan — Cosette in the U.S. Ondif — Hypera in Brazil Emylif — Zambon in Europe Libervant (coming January 11, 2027) The upfront payment (I'm guessing between $30M-$40M) will be huge and then the revenues from manufacturing it will be huge. The royalties will be single digit, but AQST's bread and butter on these deals is the manufacturing part of it all. People, erroneously, keep looking at AQST as a 1 trick pony with Anaphylm. I pity them.

$AQST Base case is a class 2 resubmission with a target of approval mid Jan. Any earlier is just bonus. Chances of approval are high, and I like the team in place to launch. Libervant is the big x factor. I know management has indicated they are looking for a commercial partner. I have no insight into the progress on this initiative. Probability they are successful? No idea. Just because management said it does not mean it gets done. If they are unable to bring in a partner, what kind of resources would they put towards its launch? We have a large short position that will continue schenanigans until they decide to go elsewhere. The shorts were in control of iova for a long time. Even positive PR's resulted in a declining stock price. This continued until they lost control and are started moving out. As a result, the stock price has exploded. AQST feels like a coiled spring that has forces keeping it at bay. Libervant may be the key in the near term. We shall see.

$AQST I enjoyed the presentation today. The company outlook is strong moving forward. Will be interesting to see how the SP plays in a tough month. But I expect the cloudy skies will pass sooner than later and the line-up of catalysts they have coming make this is a sound Long investment. $7 and then $10 over the next 6 months is very easy to digest. GL to Longs and Bulls.

$AQST Thank You Captain Obvious. Do you have any brilliant revelations for us this morning?? Like maybe the sun will rise in the east??? Idiot

$AQST All the boxes are checked for a automatic class 2 determination. Anything that needs substantial review such as new clinical data, new PK, new HF validation. AQST had to do a HF validation study and a new confirmatory PK/PD study. Thats stamped as an automatic class 2. AQST can argue all they want. All the FDA cares about are what boxes are checked. The FDA is a government entity and therefore is robotic. Context is irrelevant. How elementary and easy the HF and PK/PD studies were, the FDA simply says 'our rules say Class 2, so it's Class 2. Especially when dealing with an emergency, life or death product. Given how retarded the FDA was on requiring the PK study attached to the packaging changes, even though it was unwarranted, means they are treating this like a bunch of nervous nellies. That itself screams 6 month review. Now, that doesn't mean it can't be approved earlier than 6 months. It's just very low odds. I'd say 5% chance for Class 1, two month review.

$AQST just as I expected this week NDA submission. Let see if we can rally back up with strong volume. I don't see too many down days baring geo political events. Finally our time has arrived 2 months 4 months or 6.months. GL fellow longs

$AQST I own a nice position here. But since the CRL I just put it on a back burner while paying more attention on my other, more in the news, biotechs. But looking this morning a bit closer, I'm realizing how cheap this stock really is. The Market Cap (MC) is just a bit over $600MM. It would be an easy BO in the $2B range. With a product that could disrupt the current market for the treatment of Type I allergic reactions, including anaphylaxis, they should demand much more. For me, $2B would be a joke. I hope the price appreciates to the point were we could get something closer to $5B.

$AQST w/in the next two weeks we should hear on AQST resubmission and whether Class 1 or 2. Expecting SPRY's playbook, meaning Class 2 but early decision. AQST's CRL was lot simpler.

$AQST Additional of new board member seems to be a signal that the company is going to go it alone post approval. Otherwise, why add him? Either way, it’s a winner.

$AQST SPRY has done us no favors short-term with their collosal commercialization failure. Totally different products and totally different management like night (SPRY) and day (AQST). Long-term this shines!

$AQST Added at $4.80. Listened to Barber call this week and as bullish as ever. Holding 60k shares at $4.55 long and strong. LFG.